These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31323163)

  • 1. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
    Schauer C; van Rijnsoever M; Gane E
    J Viral Hepat; 2019 Dec; 26(12):1372-1376. PubMed ID: 31323163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing burden of advanced hepatocellular carcinoma in New Zealand-the need for better surveillance.
    Schauer C; Mules T; Rijnsoever MV; Gane E
    N Z Med J; 2020 May; 133(1515):25-34. PubMed ID: 32438374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis.
    Abara WE; Spradling P; Zhong Y; Moorman A; Teshale EH; Rupp L; Gordon SC; Schmidt M; Boscarino JA; Daida YG; Holmberg SD;
    J Gastrointest Cancer; 2020 Jun; 51(2):461-468. PubMed ID: 31124041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
    Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
    Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand.
    Somboon K; Siramolpiwat S; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(8):3567-70. PubMed ID: 24870758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients.
    Albeldawi M; Soliman M; Lopez R; Zein NN
    Dig Dis Sci; 2012 Dec; 57(12):3265-70. PubMed ID: 22695885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent and additive interaction between tumor necrosis factor β +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study.
    Jeng JE; Wu HF; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
    Asian Pac J Cancer Prev; 2014; 15(23):10209-15. PubMed ID: 25556449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiology of hepatocellular carcinoma in a rural area. Role of hepatotrophic viruses on survival].
    Rodríguez-Vidigal FF; Baz MJ; Romero J; del Puerto M
    An Med Interna; 2005 Apr; 22(4):162-6. PubMed ID: 16004511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.
    Marcon PDS; Tovo CV; Kliemann DA; Fisch P; de Mattos AA
    World J Gastroenterol; 2018 Feb; 24(5):613-622. PubMed ID: 29434450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
    Yang JD; Mohamed HA; Cvinar JL; Gores GJ; Roberts LR; Kim WR
    Am J Gastroenterol; 2016 Nov; 111(11):1573-1580. PubMed ID: 27527741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral hepatitis and hepatocellular carcinoma.
    Marrero CR; Marrero JA
    Arch Med Res; 2007 Aug; 38(6):612-20. PubMed ID: 17613352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J
    J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.